Myriad Genetics (MYGN) Change in Receivables: 2009-2025
Historic Change in Receivables for Myriad Genetics (MYGN) over the last 16 years, with Sep 2025 value amounting to -$19.0 million.
- Myriad Genetics' Change in Receivables fell 331.71% to -$19.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.6 million, marking a year-over-year decrease of 166.09%. This contributed to the annual value of $8.7 million for FY2024, which is 30.40% down from last year.
- As of Q3 2025, Myriad Genetics' Change in Receivables stood at -$19.0 million, which was down 217.28% from $16.2 million recorded in Q2 2025.
- In the past 5 years, Myriad Genetics' Change in Receivables registered a high of $17.5 million during Q1 2023, and its lowest value of -$19.0 million during Q3 2025.
- Its 3-year average for Change in Receivables is $1.6 million, with a median of $600,000 in 2024.
- In the last 5 years, Myriad Genetics' Change in Receivables plummeted by 1,120.00% in 2022 and then spiked by 2,600.00% in 2025.
- Myriad Genetics' Change in Receivables (Quarterly) stood at -$3.0 million in 2021, then climbed by 16.67% to -$2.5 million in 2022, then skyrocketed by 52.00% to -$1.2 million in 2023, then slumped by 233.33% to -$4.0 million in 2024, then slumped by 331.71% to -$19.0 million in 2025.
- Its Change in Receivables stands at -$19.0 million for Q3 2025, versus $16.2 million for Q2 2025 and -$800,000 for Q1 2025.